Back to Search Start Over

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Authors :
Enriqueta Felip
Helena Linardou
Fabrice Barlesi
Michele Maio
Luis Paz-Ares
Jonathan W Goldman
Karim Vermaelen
Osvaldo Arén Frontera
Erika Rijavec
Kevin Jao
Clarisse Audigier-valette
Han Chang
David R Spigel
Neal E Ready
Tudor-Eliade Ciuleanu
María Rosario García Campelo
Stéphanie Bordenave
Laszlo Urban
Jean-Sébastien Aucoin
Cristina Zannori
Alessandra Curioni Fontecedro
Amparo Sánchez-Gastaldo
Oscar Juan-Vidal
Elena Poddubskaya
Samreen Ahmed
Sunney Li
Joseph Fiore
Angelic Acevedo
Source :
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)
Publication Year :
2023
Publisher :
BMJ Publishing Group, 2023.

Abstract

Background CheckMate 817, a phase 3B study, evaluated flat-dose nivolumab plus weight-based ipilimumab in patients with metastatic non-small cell lung cancer (NSCLC). Here, in this research, we report on first-line treatment in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0–1 (cohort A) and special populations (cohort A1: ECOG PS 2; or ECOG PS 0–1 with untreated brain metastases, renal impairment, hepatic impairment, or controlled HIV infection).Methods Cohorts A and A1 received nivolumab 240 mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks. The primary endpoint was the incidence of grade 3–4 and grade 5 immune-mediated adverse events (IMAEs; adverse events (AEs) deemed potentially immune-related, occurring

Details

Language :
English
ISSN :
20511426
Volume :
11
Issue :
2
Database :
Directory of Open Access Journals
Journal :
Journal for ImmunoTherapy of Cancer
Publication Type :
Academic Journal
Accession number :
edsdoj.299f8904a44340aa8e9fdf450ecbbc4b
Document Type :
article
Full Text :
https://doi.org/10.1136/jitc-2022-006127